{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:29:21Z","timestamp":1791772161956,"version":"4.3.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12931-017-0683-x","type":"journal-article","created":{"date-parts":[[2017,11,25]],"date-time":"2017-11-25T04:23:58Z","timestamp":1511583838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Efficacy and safety of tiotropium and olodaterol in COPD: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9850-9520","authenticated-orcid":false,"given":"Marc","family":"Miravitlles","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Urrutia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander G.","family":"Mathioudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Ancochea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,25]]},"reference":[{"key":"683_CR1","first-page":"128","volume":"53","author":"CF Vogelmeier","year":"2017","unstructured":"Vogelmeier CF, Criner GJ, Mart\u00ednez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Arch Bronconeumol. 2017;53:128\u201349.","journal-title":"Arch Bronconeumol"},{"key":"683_CR2","first-page":"CD010844","volume":"3","author":"KM Kew","year":"2014","unstructured":"Kew KM, Dias S, Cates CJ. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis. Cochrane Database Syst Rev. 2014;3:CD010844.","journal-title":"Cochrane Database Syst Rev"},{"issue":"15","key":"683_CR3","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","volume":"359","author":"DP Tashkin","year":"2008","unstructured":"Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543\u201354.","journal-title":"N Engl J Med"},{"issue":"1","key":"683_CR4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/jamp.2012.1012","volume":"27","author":"AG Mathioudakis","year":"2014","unstructured":"Mathioudakis AG, Kanavidis P, Chatzimavridou-Grigoriadou V, Gialmanidis IP, Amanetopoulou SG, Christopoulou E, et al. Tiotropium HandiHaler improves the survival of patients with COPD: a systematic review and meta-analysis. J Aerosol Med Pulm Drug Deliv. 2014;27(1):43\u201350.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"issue":"2","key":"683_CR5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/1753465815624612","volume":"10","author":"M Schlueter","year":"2016","unstructured":"Schlueter M, Gonzalez-Rojas N, Baldwin M, Groenke L, Voss F, Reason T. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting \u03b22-agonists: a systematic review and network meta-analysis. Ther Adv Respir Dis. 2016;10(2):89\u2013104.","journal-title":"Ther Adv Respir Dis"},{"key":"683_CR6","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2147\/COPD.S130482","volume":"12","author":"GJ Rodrigo","year":"2017","unstructured":"Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, et al. LABA\/LAMA combinations versus LAMA monotherapy or LABA\/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:907\u201322.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"683_CR7","doi-asserted-by":"publisher","unstructured":"Horita N, Goto A, Shibata Y, Ota E, Nakashima K, Nagai K, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews 2017, Issue 2. Art. No.: CD012066. DOI: \nhttps:\/\/doi.org\/10.1002\/14651858\n\n. CD012066.pub2.","DOI":"10.1002\/14651858"},{"key":"683_CR8","first-page":"324","volume":"53","author":"M Miravitlles","year":"2017","unstructured":"Miravitlles M, Soler-Catalu\u00f1a JJ, Calle M, Molina J, Almagro P, Quintano JA, et al. Spanish COPD guidelines (GesEPOC) 2017. Pharmacological treatment of stable chronic obstructive pulmonary disease. Arch Bronconeumol. 2017;53:324\u201335.","journal-title":"Arch Bronconeumol"},{"key":"683_CR9","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2147\/COPD.S61717","volume":"9","author":"GT Ferguson","year":"2014","unstructured":"Ferguson GT, Feldman GJ, Hofbauer P, Hamilton A, Allen L, Korducki L, et al. Efficacy and safety of olodaterol once daily delivered via Respimat\u00ae in patients with GOLD 2-4 COPD: results from two replicate 48-week studies. Int J Chron Obstruct Pulmon Dis. 2014;9:629\u201345.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"683_CR10","doi-asserted-by":"crossref","unstructured":"Calzetta L, Ciaprini C, Puxeddu E, Cazzola M. Olodaterol + tiotropium bromide for the treatment of COPD. Expert Rev Respir Med. 2016:1\u20138.","DOI":"10.1586\/17476348.2016.1156538"},{"key":"683_CR11","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.2147\/COPD.S92840","volume":"11","author":"E Derom","year":"2016","unstructured":"Derom E, Brusselle GG, Joos GF. Efficacy of tiotropium-olodaterol fixed-dose combination in COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:3163\u201377.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"683_CR12","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","journal-title":"BMJ"},{"key":"683_CR13","unstructured":"Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from \nwww.handbook.cochrane.org\n\n."},{"key":"683_CR14","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2147\/COPD.S72482","volume":"9","author":"R ZuWallack","year":"2014","unstructured":"ZuWallack R, Allen L, Hernandez G, Ting N, Abrahams R. Efficacy and safety of combining olodaterol Respimat\u00ae and tiotropium HandiHaler\u00ae in patients with COPD: results of two randomized, double-blind, active-controlled studies. Int J Chron Obstruct Pulmon Dis. 2014;9:1133\u201344.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"683_CR15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/COPD.S95055","volume":"11","author":"KM Beeh","year":"2016","unstructured":"Beeh KM, Derom E, Echave-Sustaeta J, Gr\u00f6nke L, Hamilton A, Zhai D, et al. The lung function profile of once-daily tiotropium and olodaterol via Respimat\u00ae is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler\u00ae (ENERGITO\u00ae study). Int J Chron Obstruct Pulmon Dis. 2016;11:193\u2013205.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"683_CR16","unstructured":"Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients. [Accessed December 12, 2014]. \nClinicalTrials.gov\n\n Identifier: NCT01533922; 2012 [updated April 30, 2014]. Available from: \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT01533922\n\n."},{"key":"683_CR17","unstructured":"Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients. [Accessed December 12, 2014]. \nClinicalTrials.gov\n\n Identifier: NCT01533935; 2012 [updated April 30, 2014]. Available from: \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/\n\n\n                    \nNCT01533935\n\n."},{"issue":"10","key":"683_CR18","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.rmed.2015.08.002","volume":"109","author":"D Singh","year":"2015","unstructured":"Singh D, Ferguson GT, Bolitschek J, Gr\u00f6nke L, Hallmann C, Bennett N, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med. 2015;109(10):1312\u20139.","journal-title":"Respir Med"},{"issue":"1","key":"683_CR19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12931-016-0387-7","volume":"17","author":"D Singh","year":"2016","unstructured":"Singh D, Gaga M, Schmidt O, Bjermer L, Gr\u00f6nke L, Vo\u00df F, et al. Effects of tiotropium+olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO\u00ae studies. Respir Res. 2016;17(1):73.","journal-title":"Respir Res"},{"issue":"4","key":"683_CR20","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1183\/09031936.00136014","volume":"45","author":"R Buhl","year":"2015","unstructured":"Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4). Eur Respir J. 2015;45(4):969\u201379.","journal-title":"Eur Respir J"},{"issue":"6","key":"683_CR21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s12325-015-0218-0","volume":"32","author":"GT Ferguson","year":"2015","unstructured":"Ferguson GT, Fle\u017ear M, Korn S, Korducki L, Gr\u00f6nke L, Abrahams R, et al. Efficacy of Tiotropium + Olodaterol in patients with chronic obstructive pulmonary disease by initial disease severity and treatment intensity: a post hoc analysis. Adv Ther. 2015;32(6):523\u201336.","journal-title":"Adv Ther"},{"key":"683_CR22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.pupt.2015.04.002","volume":"32","author":"KM Beeh","year":"2015","unstructured":"Beeh KM, Westerman J, Kirsten AM, H\u00e9bert J, Gr\u00f6nke L, Hamilton A, et al. The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2015;32:53\u20139.","journal-title":"Pulm Pharmacol Ther"},{"issue":"4","key":"683_CR23","doi-asserted-by":"crossref","first-page":"e010109","DOI":"10.1136\/bmjopen-2015-010109","volume":"6","author":"J Bourbeau","year":"2016","unstructured":"Bourbeau J, Lavoie KL, Sedeno M, De Sousa D, Erzen D, Hamilton A, et al. Behaviour-change intervention in a multicentre, randomised, placebo-controlled COPD study: methodological considerations and implementation. BMJ Open. 2016;6(4):e010109.","journal-title":"BMJ Open"},{"issue":"4","key":"683_CR24","doi-asserted-by":"crossref","first-page":"e010106","DOI":"10.1136\/bmjopen-2015-010106","volume":"6","author":"T Troosters","year":"2016","unstructured":"Troosters T, Bourbeau J, Maltais F, Leidy N, Erzen D, De Sousa D, et al. Enhancing exercise tolerance and physical activity in COPD with combined pharmacological and non-pharmacological interventions: PHYSACTO randomised, placebo-controlled study design. BMJ Open. 2016;6(4):e010106.","journal-title":"BMJ Open"},{"key":"683_CR25","unstructured":"Comparing the Efficacy of Tiotropium + Olodaterol (5\/5 \u03bcg) Fixed Dose Combination (FDC) Over Tiotropium 5 \u03bcg in Reducing Moderate to Severe Exacerbations in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease. [Accessed December 12, 2014]. \nClinicalTrials.gov\n\n Identifier: NCT02296138; 2014 [updated December 11, 2014]. Available from: \nhttp:\/\/clinicaltrials.gov\/ct2\/show\/\n\n\n                    \nNCT02296138\n\n."},{"issue":"9","key":"683_CR26","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s12325-015-0239-8","volume":"32","author":"R Aalbers","year":"2015","unstructured":"Aalbers R, Maleki-Yazdi MR, Hamilton A, Waitere-Wijker S, Zhao Y, Amatto VC, et al. Randomized, double-blind, dose-finding study for Tiotropium when added to Olodaterol, administered via the Respimat\u00ae inhaler in patients with chronic obstructive pulmonary disease. Adv Ther. 2015;32(9):809\u201322.","journal-title":"Adv Ther"},{"issue":"suppl 2","key":"683_CR27","doi-asserted-by":"publisher","first-page":"A186","DOI":"10.1136\/thoraxjnl-2014-206260.378","volume":"69","author":"F Maltais","year":"2014","unstructured":"Maltais F, G\u00e1ldiz Iturri JB, Kirsten A, Singh D, Hamilton A, Tetzlaff K, et al. (P250) effects of 12 weeks of once-daily tiotropium and olodaterol fixed-dose combination on exercise endurance in patients with COPD. Thorax. 2014;69(suppl 2):A186\u20137. \nhttps:\/\/doi.org\/10.1136\/thoraxjnl-2014-206260.378\n\n.","journal-title":"Thorax"},{"issue":"6","key":"683_CR28","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1183\/09031936.00200212","volume":"42","author":"ED Bateman","year":"2013","unstructured":"Bateman ED, Ferguson GT, Barnes N, Gallagher N, Green Y, Henley M, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42(6):1484\u201394.","journal-title":"Eur Respir J"},{"issue":"6","key":"683_CR29","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S2213-2600(14)70065-7","volume":"2","author":"M Decramer","year":"2014","unstructured":"Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472\u201386.","journal-title":"Lancet Respir Med"},{"key":"683_CR30","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s12890-015-0092-1","volume":"15","author":"D Singh","year":"2015","unstructured":"Singh D, Worsley S, Zhu CQ, Hardaker L, Church A. Umeclidinium\/vilanterol versus fluticasone propionate\/salmeterol in COPD: a randomised trial. BMC Pulm Med. 2015;15:91.","journal-title":"BMC Pulm Med."},{"issue":"4","key":"683_CR31","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1183\/13993003.00216-2016","volume":"48","author":"C Vogelmeier","year":"2016","unstructured":"Vogelmeier C, Paggiaro PL, Dorca J, Sliwinski P, Mallet M, Kirsten AM, et al. Efficacy and safety of aclidinium\/formoterol versus salmeterol\/fluticasone: a phase 3 COPD study. Eur Respir J. 2016;48(4):1030\u20139.","journal-title":"Eur Respir J"},{"issue":"1","key":"683_CR32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(12)70052-8","volume":"1","author":"CF Vogelmeier","year":"2013","unstructured":"Vogelmeier CF, Bateman ED, Pallante J, Alagappan VK, D'Andrea P, Chen H, et al. Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study. Lancet Respir Med. 2013;1(1):51\u201360.","journal-title":"Lancet Respir Med"},{"key":"683_CR33","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2147\/COPD.S102962","volume":"11","author":"TM Siler","year":"2016","unstructured":"Siler TM, Donald AC, O'Dell D, Church A, Fahy WAA. Randomized, parallel-group study to evaluate the efficacy of umeclidinium\/vilanterol 62.5\/25 \u03bcg on health-related quality of life in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:971\u20139.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"683_CR34","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1080\/15412555.2017.1350154","volume":"14","author":"A Nibber","year":"2017","unstructured":"Nibber A, Chisholm A, Soler-Catalu\u00f1a JJ, Alcazar B, Price D, Miravitlles M. On behalf of the respiratory effectiveness group. Validating the concept of COPD control: a real-world cohort study from the United Kingdom. COPD. 2017;14:504\u201312.","journal-title":"COPD"},{"key":"683_CR35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s12890-015-0077-0","volume":"15","author":"CR Jenkins","year":"2015","unstructured":"Jenkins CR, Postma DS, Anzueto AR, Make BJ, Peterson S, Eriksson G, et al. Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease. BMC Pulm Med. 2015;15:97.","journal-title":"BMC Pulm Med"},{"issue":"6","key":"683_CR36","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1177\/1753465814559209","volume":"8","author":"F Maltais","year":"2014","unstructured":"Maltais F, Singh S, Donald AC, Crater G, Church A, Goh AH, et al. Effects of a combination of umeclidinium\/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Ther Adv Respir Dis. 2014;8(6):169\u201381.","journal-title":"Ther Adv Respir Dis"},{"key":"683_CR37","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.rmed.2016.11.011","volume":"122","author":"R Buhl","year":"2017","unstructured":"Buhl R, Magder S, Bothner U, Tetzlaff K, Vo\u00df F, Loaiza L, et al. Long-term general and cardiovascular safety of tiotropium\/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease. Respir Med. 2017;122:58\u201366.","journal-title":"Respir Med"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-017-0683-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,11,25]],"date-time":"2017-11-25T04:24:31Z","timestamp":1511583871000},"score":1,"resource":{"primary":{"URL":"https:\/\/respiratory-research.biomedcentral.com\/articles\/10.1186\/s12931-017-0683-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,25]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["683"],"URL":"https:\/\/doi.org\/10.1186\/s12931-017-0683-x","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,25]]},"article-number":"196"}}